These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 25495135)

  • 1. Multicenter COMPACT study of COMplications in patients with sickle cell disease and utilization of iron chelation therapy.
    Jordan L; Adams-Graves P; Kanter-Washko J; Oneal PA; Sasane M; Vekeman F; Bieri C; Magestro M; Marcellari A; Duh MS
    Curr Med Res Opin; 2015 Mar; 31(3):513-23. PubMed ID: 25495135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
    Blinder MA; Vekeman F; Sasane M; Trahey A; Paley C; Duh MS
    Pediatr Blood Cancer; 2013 May; 60(5):828-35. PubMed ID: 23335275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.
    Vekeman F; Sasane M; Cheng WY; Ramanakumar AV; Fortier J; Qiu Y; Duh MS; Paley C; Adams-Graves P
    J Med Econ; 2016; 19(3):292-303. PubMed ID: 26618853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload.
    Fung EB; Harmatz P; Milet M; Ballas SK; De Castro L; Hagar W; Owen W; Olivieri N; Smith-Whitley K; Darbari D; Wang W; Vichinsky E;
    Am J Hematol; 2007 Apr; 82(4):255-65. PubMed ID: 17094096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transfusional Iron Overload in a Cohort of Children with Sickle Cell Disease: Impact of Magnetic Resonance Imaging, Transfusion Method, and Chelation.
    Stanley HM; Friedman DF; Webb J; Kwiatkowski JL
    Pediatr Blood Cancer; 2016 Aug; 63(8):1414-8. PubMed ID: 27100139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
    Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
    J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease.
    Badawy SM; Liem RI; Rigsby CK; Labotka RJ; DeFreitas RA; Thompson AA
    Br J Haematol; 2016 Nov; 175(4):705-713. PubMed ID: 27507431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-Related Emergency Department Reliance in Patients with Sickle Cell Disease.
    Blinder MA; Duh MS; Sasane M; Trahey A; Paley C; Vekeman F
    J Emerg Med; 2015 Oct; 49(4):513-522.e1. PubMed ID: 25910824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sickle Cell Disease in an Older Adult Population: A Retrospective Review of Health Care Resource Utilization.
    Ryan JL; Rastegar JS; Dobbins JM; Peikes DN; Theodorou A; Garcia B; Loy B; Bell E; Olayiwola JN
    Popul Health Manag; 2024 Apr; 27(2):120-127. PubMed ID: 38394231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron overload in adults with sickle cell disease who have received intermittent red blood cell transfusions.
    Pack-Mabien A; Brown B; Herbert DE; Haynes J
    J Am Assoc Nurse Pract; 2015 Oct; 27(10):591-6. PubMed ID: 25711464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
    Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.
    Vekeman F; Cheng WY; Sasane M; Huynh L; Duh MS; Paley C; Mesa RA
    Leuk Lymphoma; 2015; 56(10):2803-11. PubMed ID: 25676036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease.
    Ballas SK
    Semin Hematol; 2001 Jan; 38(1 Suppl 1):30-6. PubMed ID: 11206959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
    Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
    JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019.
    Tang AY; Zhou M; Maillis AN; Lai KW; Lane PA; Snyder AB
    Pediatr Blood Cancer; 2023 Mar; 70(3):e30152. PubMed ID: 36579749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How we manage iron overload in sickle cell patients.
    Coates TD; Wood JC
    Br J Haematol; 2017 Jun; 177(5):703-716. PubMed ID: 28295188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
    Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
    Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid doses and acute care utilization outcomes for adults with sickle cell disease: ED versus acute care unit.
    Molokie RE; Montminy C; Dionisio C; Farooqui MA; Gowhari M; Yao Y; Suarez ML; Ezenwa MO; Schlaeger JM; Wang ZJ; Wilkie DJ
    Am J Emerg Med; 2018 Jan; 36(1):88-92. PubMed ID: 28802541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of red blood cell exchange, partial manual exchange, and simple transfusion concurrently with iron chelation therapy in reducing iron overload in chronically transfused sickle cell anemia patients.
    Fasano RM; Leong T; Kaushal M; Sagiv E; Luban NL; Meier ER
    Transfusion; 2016 Jul; 56(7):1707-15. PubMed ID: 26997031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.